These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 8686009

  • 1. [Autologous stem cell transplantation. From bone marrow to selected blood stem cells: 100 consecutive procedures at a single center].
    Geisler CH, Simonsen AC, Mortensen BT, Christensen LD, Ersbøll JK, Andersen NS, Dickmeiss E, Hansen MM.
    Ugeskr Laeger; 1996 Apr 29; 158(18):2546-51. PubMed ID: 8686009
    [Abstract] [Full Text] [Related]

  • 2. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
    Ganguly S, Divine CL, Deauna-Limayo D, Bodensteiner DC, Cook JD, Lewis JN, Skikne BS.
    Ann Hematol; 2005 Aug 29; 84(8):526-31. PubMed ID: 15915350
    [Abstract] [Full Text] [Related]

  • 3. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D, Miller J, Verfaillie C, Burns L, Wagner J, Blazar B, Davies S, Miller W, Hannan P, Steinbuch M, Ramsay N, McGlave P.
    Biol Blood Marrow Transplant; 1997 Oct 29; 3(4):217-23. PubMed ID: 9360784
    [Abstract] [Full Text] [Related]

  • 4. Autologous bone marrow/stem cell transplantation: initial experience at a north Indian referral centre.
    Gupta S, Kumar L, Raju GM, Kochupillai V, Shukla DK.
    Natl Med J India; 2000 Oct 29; 13(2):61-6. PubMed ID: 10835851
    [Abstract] [Full Text] [Related]

  • 5. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
    Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L, Vidriales B, del Cañizo MC, Corral M, Gonzalez M, León A, Jean-Paul E, Rocha E, Moraleda JM, San Miguel JF.
    Bone Marrow Transplant; 1997 Sep 29; 20(6):451-8. PubMed ID: 9313877
    [Abstract] [Full Text] [Related]

  • 6. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K, Margolin K, Champlin R, Forman S.
    Cancer J Sci Am; 1997 Dec 29; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [Abstract] [Full Text] [Related]

  • 7. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation.
    Sobecks RM, Le Beau MM, Anastasi J, Williams SF.
    Bone Marrow Transplant; 1999 Jun 29; 23(11):1161-5. PubMed ID: 10382956
    [Abstract] [Full Text] [Related]

  • 8. [Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
    Wójcik B, Kowalczyk JR, Chybicka A, Wachowiak J, Drabko K, Zaucha-Prazmo A, Choma M, Gorczyńska E, Toporski J, Turkiewicz D, Kałwak K, Pieczonka A, Boruczkowski D.
    Przegl Lek; 2004 Jun 29; 61 Suppl 2():53-6. PubMed ID: 15686047
    [Abstract] [Full Text] [Related]

  • 9. [Difference in costs of autologous transplantation of peripheral and bone marrow hematopoietic stem cells. A retrospective analysis over 1 year of transplantation in lymphoma, Hodgkin's disease and myeloma in a Center].
    Rio B, Marjanovic Z, Belhocine R, Vekhoff A, Andrieu V, Klaren J, Boccaccio C, Delmer A, Ajchenbaum-Cymbalista F, Hunault M, Bazarbachi A, Lévy V, Andreu G, Zittoun R.
    Ann Med Interne (Paris); 1996 Jun 29; 147(5):313-9. PubMed ID: 9033732
    [Abstract] [Full Text] [Related]

  • 10. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
    Lazarus HM, Loberiza FR, Zhang MJ, Armitage JO, Ballen KK, Bashey A, Bolwell BJ, Burns LJ, Freytes CO, Gale RP, Gibson J, Herzig RH, LeMaistre CF, Marks D, Mason J, Miller AM, Milone GA, Pavlovsky S, Reece DE, Rizzo JD, van Besien K, Vose JM, Horowitz MM.
    Bone Marrow Transplant; 2001 Feb 29; 27(4):387-96. PubMed ID: 11313668
    [Abstract] [Full Text] [Related]

  • 11. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
    Wang S, Nademanee A, Qian D, Dagis A, Park HS, Fridey J, Smith E, Snyder D, Somlo G, Stein A, Rosenthal J, Falk P, Kogut N, Palmer J, Gaal K, Kim Y, Bhatia R, Yuan S, Kay C, Weiss L, Forman S.
    Transfusion; 2007 Dec 29; 47(12):2207-16. PubMed ID: 17714420
    [Abstract] [Full Text] [Related]

  • 12. Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantation.
    Novotny JR, Rosenthal C, Elmaagacli AH, Dürig J, Beelen DW, Dührsen U.
    Eur J Haematol; 2004 Jul 29; 73(1):1-9. PubMed ID: 15182331
    [Abstract] [Full Text] [Related]

  • 13. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
    Dann EJ, Daugherty CK, Larson RA.
    Bone Marrow Transplant; 1997 Sep 29; 20(5):369-74. PubMed ID: 9339751
    [Abstract] [Full Text] [Related]

  • 14. [High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich].
    Jost LM, Honegger HP, Stahel RA.
    Schweiz Med Wochenschr; 2000 Jan 22; 130(3):60-9. PubMed ID: 10683881
    [Abstract] [Full Text] [Related]

  • 15. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
    Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T, Santini G, Blaise D, Greinix H, Ferrant A, Cornelissen J, Schmitz N, Goldstone AH, European Bone Marrow Transplantation (EBMT) Lymphoma Registry.
    Bone Marrow Transplant; 2003 Apr 22; 31(8):667-78. PubMed ID: 12692607
    [Abstract] [Full Text] [Related]

  • 16. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A, Hardan I, Shpilberg O, Raanani P, Grotto I, Ben-Bassat I.
    Harefuah; 2000 Sep 22; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [Abstract] [Full Text] [Related]

  • 17. Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience.
    Ballova V, Ladicka M, Vranovsky A, Lakota J.
    Neoplasma; 2008 Sep 22; 55(5):428-36. PubMed ID: 18665754
    [Abstract] [Full Text] [Related]

  • 18. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
    Bierman PJ, Sweetenham JW, Loberiza FR, Taghipour G, Lazarus HM, Rizzo JD, Schmitz N, van Besien K, Vose JM, Horowitz M, Goldstone A, Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
    J Clin Oncol; 2003 Oct 15; 21(20):3744-53. PubMed ID: 12963703
    [Abstract] [Full Text] [Related]

  • 19. Haemopoietic stem cell transplantation in Australia and New Zealand, 1992-2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry.
    Nivison-Smith I, Bradstock KF, Dodds AJ, Hawkins PA, Szer J.
    Intern Med J; 2005 Jan 15; 35(1):18-27. PubMed ID: 15667464
    [Abstract] [Full Text] [Related]

  • 20. Autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma.
    Bolwell BJ.
    Semin Oncol; 1994 Aug 15; 21(4 Suppl 7):86-95. PubMed ID: 7916488
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.